Zoetis Inc.
Zoetis Inc. is a U.S.-based animal health company focused on medicines, vaccines, diagnostics, biodevices, genetic tests, and precision animal health products. Its portfolio serves companion animals and livestock across more than 100 countries through direct sales and distributor channels.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueProducts used to prevent and treat parasites in companion animals and livestock.
Immunization products for companion animal and livestock disease prevention.
Therapies for skin and allergy conditions in companion animals.
Antibiotic and infection-control products used mainly in livestock and veterinary care.
Products used for pain control, anesthesia, and procedural sedation in animals.
Diagnostics, biodevices, genetic tests, and other veterinary health services.
Customers
Zoetis sells primarily to veterinarians and livestock producers, with products often dispensed by prescription through veterinary practices. It also serves pet owners in markets where direct-to-consumer purchasing matters, and it uses distributors, retailers, and e-commerce in selected channels and geographies.
Buy prescription medicines, vaccines, diagnostics, and support services for companion animals and livestock.
Buy products for cattle, swine, poultry, fish, and sheep to manage herd health and productivity.
Influence and sometimes purchase companion-animal products, especially where direct-to-consumer marketing matters.
Purchase and resell products or negotiate on behalf of veterinary practices in non-direct markets.
Strategy
Zoetis focuses on broadening its animal health portfolio across companion animals and livestock while maintaining direct relationships with veterinarians and producers. Its strategy also relies on R&D, product innovation, and selective acquisitions to expand diagnostics, genetics, and specialty animal health capabilities.
New and improved products help address unmet animal-health needs and sustain relevance across species.
Sales representatives and veterinary specialists help influence prescribing and build loyalty.
Local presence improves access to veterinarians and producers and supports emerging-market growth.
Acquisitions can add products, diagnostics, manufacturing capacity, and research capabilities.
Geography
Q1/2026Zoetis manages its business through two operating segments: the United States and International. It markets products in about 45 countries directly and sells in over 100 countries overall, with meaningful exposure to North America, Europe, Latin America, Asia, Australia, and Africa.
Share of the revenue the company reports by geography.
Risks
Zoetis faces customer concentration and channel-consolidation pressure, especially as veterinarians, livestock producers, and distributors gain buying power. It is also exposed to trade policy changes, tariffs, supply-chain disruption, foreign exchange volatility, cyber risk, and regulatory or market shifts affecting animal-health products and antibacterials.
- Customer and distributor consolidationImpact: HighLikelihood: Medium
Larger veterinary groups, buying cooperatives, and distributors can demand lower prices.
Exposure - Tariffs and trade restrictionsImpact: HighLikelihood: Medium
Higher duties can increase raw material, component, and finished-goods costs and disrupt supply chains.
Exposure: Global sourcing and cross-border sales
- Cybersecurity and IT disruptionImpact: HighLikelihood: Medium
Operational dependence on systems and remote work increases exposure to attacks and outages.
Exposure: Global operations and customer-facing systems
- Generic competition and channel changeImpact: MediumLikelihood: High
Generic products or shifts toward retail/e-commerce can reduce share and pricing power.
Exposure: Companion animal and livestock product lines
- Foreign exchange volatilityImpact: MediumLikelihood: Medium
International revenue and earnings are translated from multiple currencies into U.S. dollars.
Exposure
Accounting
Judgemental itemsGross product revenue is reduced by estimated returns and customer incentives recorded in the same period.
Impact: Can affect revenue timing and margin comparability across periods
The company carries acquired intangibles and goodwill that must be tested for impairment.
Impact: Could create non-cash charges if product or business values decline
Business combinations require valuation of acquired assets, liabilities, and intangibles.
Impact: Affects purchase accounting, amortization, and future earnings
Legal, regulatory, and tax positions require judgment and can change with new information.
Impact: May create volatility in provisions and effective tax rate
Similar listed companies
Publicly listed companies with a comparable business focus.
Zomedica Corp.
ZOMDF · Pharmaceutical Preparations
Neogen Corporation
NEOG · In Vitro & In Vivo Diagnostic Substances
Neogen Corp develops and sells products and services used to test food, feed, and agricultural inputs for safety and quality, while also providing genomics and animal safety solutions.
Elanco Animal Health Inc
ELAN · Pharmaceutical Preparations
Elanco Animal Health is a U.S.-based animal health company that develops and sells medicines, vaccines, feed additives and related services for pets and farm animals.
Zentalis Pharmaceuticals, Inc.
ZNTL · Pharmaceutical Preparations
Zentalis Pharmaceuticals is a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing small-molecule cancer therapies.
Zhengye Biotechnology Holding Ltd
ZYBT · Pharmaceutical Preparations
Zhengye Biotechnology Holding Ltd is a Cayman Islands holding company with operating activities centered in Jilin, China through its veterinary vaccine business.
Pelthos Therapeutics Inc.
PTHS · Biological Products, (No Diagnostic Substances)
Last updated: 24/09/2026